Shopping Cart
- Remove All
- Your shopping cart is currently empty
UCM-1306 is a potent and orally active allosteric modulator (PAM) of the human dopamine D1 receptor. It increases the maximal effect of endogenous dopamine (DA) in both human and mouse D1 receptors. UCM-1306 could improve motor symptoms and address key comorbid cognitive impairment associated with long-term Parkinson's disease (PD).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $31 | In Stock | |
5 mg | $73 | In Stock | |
10 mg | $118 | In Stock | |
25 mg | $238 | In Stock | |
50 mg | $353 | In Stock | |
100 mg | $506 | In Stock |
Description | UCM-1306 is a potent and orally active allosteric modulator (PAM) of the human dopamine D1 receptor. It increases the maximal effect of endogenous dopamine (DA) in both human and mouse D1 receptors. UCM-1306 could improve motor symptoms and address key comorbid cognitive impairment associated with long-term Parkinson's disease (PD). |
In vitro | UCM-1306 (1-10 μM) enhances CAMP in a concentration-response manner, EC50=60 nM[1]. |
In vivo | UCM-1306 (p.o.; C57BL/6J mice) has good brain penetration and oral availability. The plasma concentration can be quantified within 8 hours, and Tmax is 0.5 hours. UCM-1306 (1 mg/kg; ip) enhances cocaine induced hyperactivity in adult mice. UCM-1306 (1 mg/kg; ip) helps to consolidate the formation of long-term memory [1]. |
Molecular Weight | 279.33 |
Formula | C14H14FNO2S |
Cas No. | 2258608-78-3 |
Smiles | CS(=N)(=O)c1ccc(cc1)-c1ccccc1OCF |
Relative Density. | 1.21 g/cm3 (Predicted) |
Storage | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 45.0 mg/mL (161.1 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.